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Background: DNA methylation (DNAm) has important regulatory roles in many biological processes and diseases. It is
the only epigenetic mark with a clear mechanism of mitotic inheritance and the only one easily available on a genome
scale. Aberrant cytosine-phosphate-guanine (CpG) methylation has been discussed in the context of disease aetiology,
especially cancer. CpG hypermethylation of promoter regions is often associated with silencing of tumour suppressor
genes and hypomethylation with activation of oncogenes.
Supervised principal component analysis (SPCA) is a popular machine learning method. However, in a recent application
to phenotype prediction from DNAm data SPCA was inferior to the specific method EVORA.
Results: We present Model-Selection-SPCA (MS-SPCA), an enhanced version of SPCA. MS-SPCA applies several models
that perform well in the training data to the test data and selects the very best models for final prediction based on
parameters of the test data.
We have applied MS-SPCA for phenotype prediction from genome-wide DNAm data. CpGs used for prediction are
selected based on the quantification of three features of their methylation (average methylation difference, methylation
variation difference and methylation-age-correlation). We analysed four independent case–control datasets that
correspond to different stages of cervical cancer: (i) cases currently cytologically normal, but will later develop neoplastic
transformations, (ii, iii) cases showing neoplastic transformations and (iv) cases with confirmed cancer. The first dataset
was split into several smaller case–control datasets (samples either Human Papilloma Virus (HPV) positive or negative). We
demonstrate that cytology normal HPV+ and HPV- samples contain DNAm patterns which are associated with later
neoplastic transformations. We present evidence that DNAm patterns exist in cytology normal HPV- samples that (i)
predispose to neoplastic transformations after HPV infection and (ii) predispose to HPV infection itself. MS-SPCA performs
significantly better than EVORA.
Conclusions: MS-SPCA can be applied to many classification problems. Additional improvements could include usage of
more than one principal component (PC), with automatic selection of the optimal number of PCs. We expect that
MS-SPCA will be useful for analysing recent larger DNAm data to predict future neoplastic transformations.
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DNA methylation (DNAm) has important regulatory roles
in many biological processes and diseases. It is the only epi-
genetic mark with a clear mechanism of mitotic inheritance
[1] and the only one easily available on a genome scale for
epigenome-wide association studies [2]. In vertebrates, the
most common form of DNAm is 5-methylcytosine. It is as-
sociated with changes in DNA-protein interactions and gene
expression. High methylation levels in cytosine-phosphate-Correspondence: Thomas.wilhelm@ifr.ac.uk
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unless otherwise stated.guanine (CpG)-rich promoter regions are strongly associ-
ated with transcriptional repression [2]. Recent DNAm stud-
ies provided new etiological insights for human diseases [3].
Interestingly, epigenetic changes can be induced by diet,
with implications for health [4] and obesity [5].
Although significant progress has been made during
the last decades, cancer remains a global problem of ris-
ing importance [6]. On the other hand, modern omics
technologies also enable new approaches for fighting the
disease. ‘Epigenetic changes can be the earliest initiating
factor in a human cancer’ [7]. DNAm markers for cancer
detection have been found and potential DNAm driverThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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DNAm biomarkers indicating the risk of later cancer on-
set is improving early diagnosis and therapy.
Based on the hypothesis that epigenetic variability may
reflect differential exposure to genetic and environmen-
tal risk factors, it has been proposed that CpG sites with
high inter-individual methylation variability might indi-
cate risk of complex diseases [9]. The fact that such sites
occur more frequently in the promoters of developmen-
tal genes [9] is consistent with this hypothesis, although
sites with inter-individual variability are stable within in-
dividuals over many years [9].
Recently, a classifier based on DNAm data to predict
the risk of neoplastic development (EVORA = epigenetic
variable outliers for risk prediction analysis) has been
proposed [10]. It considers two features of a CpG’s
methylation, the level of methylation and methylation
variability. The latter is the primary feature (CpG) selec-
tion criterion, the first few hundred most hypervariable
CpGs (variability of methylation, quantified by Bartlett’s
test, is higher in case samples) are considered as ‘risk
CpGs’. The risk score of an individual sample is the frac-
tion of ‘risk CpGs’ with a methylation level higher than
a given cut-off. The optimal number of CpGs considered
as well as the optimal cut-off is found by optimizing the
Area Under the Curve (AUC) through internal cross-
validation in the training data. EVORA was superior to
the two tested popular classification algorithms PAMR
[11] and SPCA [12] (in case of PAMR and SPCA feature
selection was based on differential methylation statistics
alone) [10]. However, it is known since the first DNAm
measurements in human cancer that widespread DNA
hypomethylation is involved [13], but EVORA, by con-
sidering hypermethylated and hypervariable CpGs alone,
does not account for such sites. Indeed, promoter hypo-
methylation has been used as criterion for detecting
novel oncogenes in cancer [14]. A refined version of
EVORA was used to predict later neoplastic develop-
ment [15] in women with normal cytology according to
a cervical screening test [16]. This version considered a
third feature of CpG methylation, age-correlation. A
CpG was classified as ‘risk CpG’ only if its methylation
is both more variable in cases and positively age-
correlated [15]. The authors note that the uterine cervix
is ‘currently the only human organ allowing relatively
easy access to the cell of origin of the associated cancer
well in advance of the first morphological signs of neo-
plastic transformation’.
Supervised principal component analysis (SPCA) [12]
was developed for the prediction of tumour patients’ sur-
vival times based on gene expression data and was later
successfully applied to other classification problems. A
samples risk score corresponds to its score on the first prin-
cipal component (PC) or the corresponding score from alinear combination of several PCs (weighted by singular
values). Standard PCA is considered as an unsupervised
technique. In SPCA the features used for PCA are specific-
ally selected for best association with the phenotype of
interest (in the training data). In the original SPCA paper,
the Cox score (a measure of the correlation between a
gene’s expression level and patient survival) was used as the
association criterion [12] and only genes with a Cox score
above a given threshold were considered for PCA (singular
value decomposition). Again, the optimal threshold was ob-
tained from internal cross-validation.
Here we present Model-Selection-SPCA (MS-SPCA),
an enhanced version of SPCA. SPCA determines one
model for the prediction of test data from optimisation
within the training data. In contrast, MS-SPCA deter-
mines several models that perform well in the training
data and selects specific ones for the prediction of test
data, based on parameters of the test data. This is a nat-
ural extension of SPCA as it answers the question of
how to deal with situations where several equally well
performing models are found during the training data
internal cross-validation. MS-SPCA applies all these
models to the test data and identifies the most appropri-
ate subset of these models for final prediction.
MS-SPCA was applied to analyse publicly available
genome-wide DNAm data of cervical screening samples
(27,578 CpGs corresponding to 14,495 genes, mostly in
promoter regions [17]). The cases considered corres-
pond to three different stages of cervical cancer develop-
ment: (i) women with no cytological signs of neoplasia
that have later developed neoplastic transformations
(cervical intraepithelial neoplasia of grade 2 or higher,
CIN2+) as determined from a subsequent screen after
three years, (ii) neoplastic transformations (CIN2+, two
independent case–control datasets), (iii) fully developed
cancer.
We show that hyper- and hypomethylated, hyper- and
hypovariable and positively and negatively age-correlated
CpGs exist that are significantly associated with the
phenotype. Significant CpGs of one dataset overlap sig-
nificantly with significant CpGs of other datasets. Genes
corresponding to significant CpGs are enriched with de-
velopmental genes (polycomb group targets, PCGTs
[18]) and cervical cancer genes [19].
In contrast to EVORA, MS-SPCA uses the full non-
binary methylation information as well as hyper- and
hypomethylated sites. CpGs most associated with the
phenotype in the training data are used for prediction.
The corresponding ranked list of association strength is
created by simultaneous consideration of three features
of CpG methylation: average methylation difference,
methylation variability difference (both between cases
and controls) and age-correlation. We use a ranks-
weighting scheme to account for different weighting of
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ranking CpGs are tested by cross-validation in the train-
ing data. Therefor we have used the leave-one-out
(LOO) method (other methods such as 5- or 10-fold
cross-validation could be used instead).
We present results for all 21 possible test data predic-
tions, using either cytology normal case–control data or
CIN2+ case–control data for training. Cancer data are
not used for training because the methylation patterns
are very pronounced and would yield many thousands of
perfectly predicting models in the training data. We also
divide the cytology normal women dataset into several
age-matched subsets (either completely HPV+ or HPV-),
enabling another 50 predictions. Altogether, we per-
formed 71 predictions in comparison to EVORA. MS-
SPCA outperforms EVORA in nearly all cases. In most
cases the difference is statistically significant.
Results
We analysed six case–control datasets of genome-wide
DNAm data (from four independent datasets, see
Methods). Samples from women with normal cytology
were used as control groups in all datasets. Table 1
shows the corresponding numbers of case and control
samples.
Significantly associated CpGs
We tested all CpGs in the six datasets for average
methylation difference (t-test, Mann–Whitney U test),
methylation variation difference (Bartlett’s and Levene’s
test) and methylation-age-correlation. Table 2 shows the
numbers of corresponding significant CpGs. Each test
was done for all CpGs (first row within a table cell), or
only hyper- (row 2) and hypo-CpGs (row 3) (see
Methods, e.g. 80 significant hypovariable CpGs accord-
ing to Levene’s test in the Cancer data). The higher
number of significant hyper-CpGs may reflect the biased
CpG choice of the Illumina 27K chip [10]. Future studies
using less biased methods will clarify the relative import-
ance of hyper- and hypomethylation. Table 2 shows that
methylation patterns are more pronounced in more ad-
vanced stages of cancer. Most significant CpGs areTable 1 Datasets used
GEO Name # Cases # Controls
GSE30758 Normal 75 77
GSE30758 Normal HPV+ 44 48
GSE30758 Normal HPV- 31 29
GSE20080 CIN2+(a) 18 30
GSE37020 CIN2+(b) 24 24
GSE30759 Cancer 48 15
The four columns show the GEO [37] accession numbers, name of the datasets
and the corresponding numbers of contained case and control samples.found in the data where cases correspond to fully devel-
oped cancer, intermediate numbers are found in CIN2+
data and almost no significant CpGs are detected in the
Normal data (cases still cytology normal, but will later
develop transformations).
There are many significant CpGs in the Normal data
according to Bartlett’s test, but these CpGs are not sig-
nificant according to a permutation test. Often there is
just a single sample largely deviating from the others, so
permuting phenotypes does almost not change the p-
value (note the nearly identical number of cases and
controls). Accordingly, after permuting phenotypes of
the Normal data one gets about the same number of sig-
nificant CpGs, according to Bartlett’s test. The other
tests do not suffer from the problem, the results are al-
ways corresponding to permutation test results.
Although there are no statistically significant hyper- or
hypomethylated CpGs in the Normal data, intersection
of the most significant CpGs of these data with the most
significant CpGs of the CIN2+ and Cancer data shows a
significant overlap (Table 3), indicating that many im-
portant CpGs are hidden below the threshold for
genome-wide significance. This corresponds to a similar
finding in genome-wide association studies (GWAS)
where typically only the minority of a phenotype’s herit-
ability can be explained by the statistically significant
single-nucleotide polymorphisms (SNPs) (~100). How-
ever, taking into account all ~1 m SNPs allows explan-
ation of most of the heritability [20], ‘most of the genetic
variance is simply hidden below the threshold for
genome-wide significant associations’ [21]. Significant
CpGs in the Normal HPV+ dataset overlap more to the
corresponding CIN2+ and Cancer dataset CpGs than
Normal HPV- CpGs. This could indicate that the poten-
tial transformation causing methylation patterns are
more pronounced in the HPV+ dataset, but the number
of HPV+ samples is also higher.
Tables 4 and 5 provide additional evidence that the
most significant CpGs correspond to genes involved in
cancer onset. For best ranking CpGs, we identified the
corresponding genes and determined their overlap to
538 known cervical cancer genes [19] and 1,591 develop-
mental genes (polycomb group targets PCGT) [18].
Table 4 shows that cervical cancer genes are enriched in
nearly all high-ranking genes. Genes from the Normal
data overlap as significantly as genes from CIN2+ and
Cancer data. Hypo-CpG-genes overlap as well as hyper-
CpG-genes. Table 5 shows that hyper-CpG-genes are
highly enriched with PCGT genes [18], in contrast to
hypo-CpG-genes.
Motivation for Supervised PCA approach
Table 2 shows that no single CpG can differentiate be-
tween case and control samples in the three Normal
Table 2 Numbers of significant CpGs (q-value < 0.05) according to five different tests
Normal Normal HPV+ Normal HPV- CIN2+(a) CIN2+(b) Cancer
t
0 0 0 389 233 14811
0 0 0 452 100 10383(7)
0 0 0 8 140 4753(1)
MWU
0 0 0 403 1008 16990
0 0 0 408 372 11320(97)
0 0 0 10 646 5885(46)
Bartlett
2830 1837 1204 3035 3444 12023
1614 1154 748 2208 1948 12209
1194 707 468 847 1489 414
Levene
0 0 0 241 2 5881
0 1 0 326 4 7178
0 0 0 0 0 80
Age-corr.
16 385 68 13 89 473
16 330 75 19 52 525
1 49 13 5 31 69
t-test, Mann–Whitney U test, Bartlett’s test, Levene’s test and test for methylation-age-correlation. The three rows per cell correspond to all, hyper- and hypo-CpGs.
Numbers of most significant CpGs that are completely separating cases from controls are given in brackets.
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(PCs) corresponding to the best ranking CpGs do separ-
ate cases from controls. Additional file 1: Figure S1
shows for the Normal dataset that the leading PCs do
significantly (p < 10−15) differentiate, if the CpGs with
the highest average methylation difference are used
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39 15 28 11 55 17
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25 13 17 7 42 13
12 10 27 7 18 8
Bartlett
34 22 23 28 26 19
75 53 37 32 71 53
35 12 16 28 41 15
Levene
60 22 19 12 40 17
90 41 32 14 59 30
11 2 9 9 18 16
Age-corr.
15 32 10 107 16 30
12 43 8 138 12 37
32 38 22 49 29 30
CpGs were ordered according to five different tests (t-test, Mann–Whitney U test, B
number of overlapping CpGs between the first 500 of two datasets determined. Th
laps (p < 0.01) are shown in bold.Prediction of future neoplastic transformation, CIN2+ and
Cancer
Selecting the best models from cross-validation in training
data
We tested models based on the best ranking CpGs ac-
cording to CpG ‘combi’ orders (combining three features






















20 9 12 14 16 140 22
35 9 7 16 32 190 26
19 7 15 17 10 39 18
16 7 9 15 19 119 22
29 9 8 11 29 171 23
21 7 9 13 11 50 16
21 37 36 27 54 45 45
26 39 39 25 98 62 57
20 37 10 15 24 26 18
19 12 6 8 49 70 17
29 12 14 17 68 79 34
16 14 6 14 17 13 7
9 13 18 11 19 7 9
10 10 30 5 18 8 15
23 29 29 16 13 19 12
artlett’s test, Levene’s test and test for methylation-age-correlation) and the
e three rows per cell correspond to all, hyper- and hypo-CpGs. Significant over-
Table 4 Numbers of genes overlapping to 538 known cervical cancer genes
Normal Normal HPV+ Normal HPV- CIN2+(a) CIN2+(b) Cancer
t
39 42 45 39 40 31
43 42 38 29 40 25
43 38 44 39 46 46
MWU
37 38 46 35 47 32
38 41 42 30 41 26
39 43 45 43 51 45
Bartlett
38 42 47 36 57 49
43 40 48 37 47 46
47 42 36 44 63 41
Levene
37 48 42 40 48 46
35 46 43 39 38 46
35 40 45 43 55 38
Age-corr.
36 46 31 40 40 50
39 32 34 47 50 44
35 47 29 35 37 38
Genes corresponding to the 1000 most significant CpGs taken (five tests: t-test, Mann–Whitney U test, Bartlett’s test, Levene’s test and test for methylation-age-
correlation, mean length of gene lists: 931). The three rows per cell correspond to all, hyper- and hypo-CpGs. Significant overlaps (p < 0.01) are shown in bold.
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Methods) for cross-validation prediction in the five data-
sets that served as training data: Normal, Normal HPV+,
Normal HPV-, CIN2+(a) and CIN2+(b). In each case the
first few hundred best performing models were applied
for prediction of all the corresponding independent
datasets (Table 6, Figures 1, 2 and 3). Models with the
following cross-validation prediction accuracies wereTable 5 Numbers of genes overlapping to 1,591 developmen





















Genes corresponding to the 1000 most significant CpGs taken (five tests: t-test, Man
correlation, mean length of gene lists: 931). The three rows per cell correspond to aused: >0.65 for the three Normal datasets, >0.82 for
CIN2+(a), and >0.95 for CIN2+(b); resulting in >300 models
trained on the Normal datasets and >700 and >1000 models
trained on CIN2+(a) and CIN2+(b), respectively (Figures 2
and 3). The models predicting the training-data best
have the following accuracies: ~0.8 for the Normal data-
sets, 0.92 for CIN2+(a) and 1 for CIN2+(b) (~200 models
with accuracy 1). The clearer patterns in CIN2+(b),tal genes
















n–Whitney U test, Bartlett’s test, Levene’s test and test for methylation-age-
ll, hyper- and hypo-CpGs. Significant overlaps (p < 0.01) are shown in bold.
Table 6 Prediction performance (AUC) of MS-SPCA
Normal Normal HPV+ Normal HPV- CIN2+(a) CIN2+(b) Cancer
Normal 0.93/0.66(0.87) 0.81/0.55(0.69) 1/0.81(0.94)
Normal HPV+ 0.52/0.45 0.93/0.77 0.84/0.65 1/0.75
Normal HPV- 0.61/0.55 0.92/0.68 0.64/0.46 1/0.71
CIN2+(a) 0.60/0.57 0.63/0.60 0.53/0.54 0.83/0.71 1/0.72
CIN2+(b) 0.58/0.56 0.62/0.60 0.53/0.46 0.87/0.82(0.87) 0.98/0.85(1)
Rows correspond to training data and columns to test data. The first number shows the performance of MS-SPCA, the second the performance of EVORA (mean
value of 8 runs). Numbers in brackets show the five EVORA results as presented in [10]. Bold numbers show best predictions.
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all CIN2+(b) samples were taken from HPV infected
women.
Identifying the likely best predicting models and final
prediction
MS-SPCA selects the final models for prediction on the
basis of parameters obtained from analysis of the test
data. Figure 1 depicts the two parameters Eval1 and
EV1dist for all used models. Figure 2 shows the predic-
tion performance of all models ordered according to the
difference Eval1-EV1dist (using standardised numbersFigure 1 Two parameters - used for final model selection. Each dot co
training data. Each row corresponds to a given training dataset (name on t
header). For instance, the field row 1 (Normal) – column 4 (CIN2+(a)) show
selected from the training dataset Normal (LOO-prediction-accuracy > 0.65)
10% of the models predicting the test data best are shown in red, the nex
(between deciles 2 and 3) blue. Black dots represent the remaining 70%. Ev
from the methylation matrix of the test data. EV1dist is the Euclidean distan
in the training data and in the test data.for Eval1 and EV1dist). Eval1 is the normalized largest
eigenvalue of the covariance matrix taken from the
methylation matrix of the test data. EV1dist is the
Euclidean distance between the leading Eigenvectors of
the model’s covariance matrix in the training data and in
the test data. It can be seen from the colouring in
Figure 1 that the smaller EV1dist and the larger Eval1 is,
the more likely the model makes a good prediction of
the test data. Red dots tend to be in the lower right cor-
ner, especially for the well predicted advanced trans-
formation stages CIN2+ and cancer (least for the poorly
predicted Normal HPV- samples). Eval1 measures howrresponds to one model that performs well in cross-validation in the
he left), each column to the corresponding test dataset (name in
s the two parameters (x-axis Eval1, y-axis EV1dist) for all >300 models
, when applied to the test data CIN2+(a). For better visualization, the
t 10% (between deciles 1 and 2) are coloured green and the next
al1 is the normalized largest eigenvalue of the covariance matrix taken
ce between the leading Eigenvectors of the model’s covariance matrix
Figure 2 Performance of prediction (AUC). Each row corresponds to a given training dataset, each column to a test dataset and each dot to
one model. Models are ordered according to Eval1-EV1dist, rank 1 corresponds to the model with the largest value. Eval1 is the normalized largest
eigenvalue of the covariance matrix taken from the methylation matrix of the test data. EV1dist is the Euclidean distance between the leading
Eigenvectors of the model’s covariance matrix in the training data and in the test data. The red line shows the AUC resulting from cumulative risk
scores (see Methods). The values of the red lines at model rank 5 are given in Table 6.
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by PC1. EV1dist is a measure for how well the model
obtained from the training data fits to the test data. Im-
portantly, the two parameters Eval1 and EV1dist capture
information about how likely a model makes a good pre-
diction. For example, in the first row of Figures 1, 2 and
3 models were trained on the Normal dataset. These
models predict the CIN2+(a) and Cancer data very well
(Figure 2), but less so the CIN2+(b) data. Figure 1 shows
that Eval1 is generally smaller for CIN2+(b) models and
EV1dist is larger. Similarly in the last column: in rows 1,
2 and 4, where the prediction is very good (Figure 2),
Eval1 is often large and EV1dist is small. Parameters
such as Eval1 and EV1dist open the possibility to auto-
matically select the most appropriate number of princi-
pal components to consider for prediction. The authors
of the original SPCA paper had worked on a similar
problem but had not solved it [12]. Given that the
models trained on CIN2+(b) data have consistently poor
Eval1 and EV1dist, compared to models from other
training data, it seems that consideration of more than
one PC could improve the prediction performance.
Although the two parameters Eval1 and EV1dist are
correlated to each other they also carry importantunique information. Each parameter alone is inferior to
the sum Eval1-EV1dist. For example, row 3-column 2
shows poorly performing models with small EV1dist,
row 4-column 5 shows poor models with large Eval1.
Figure 2 shows that, although there is some variation,
the best-ranking models (low ranks) perform better.
Moreover, the cumulative score (see Methods) enables
robust and good prediction by considering only best-
ranking models. The final prediction results that cor-
respond to the AUC of the cumulative score at model
rank 5 are given in Table 6. The prediction of a given test
dataset by MS-SPCA is quite consistent, no matter which
training dataset is used: Normal ~0.6, Normal HPV+ >0.6,
Normal HPV- >0.5, CIN2+(a) >0.9, CIN2+(b) >0.8,
Cancer ~1.
Comparison with EVORA [10] was performed, using
the R-package ‘evora’. Table 6 shows the mean predic-
tion values of 8 independent runs. Prediction with MS-
SPCA is nearly always superior. The better performance
of MS-SPCA is statistically significant. A two-way
ANOVA confirms the significantly higher performance
of MS-SPCA, even in comparison to the three previously
published prediction results of row 1 (using Normal for
training): we simulated 20 EVORA-AUC values for each
Figure 3 Description of models used for predictions (weights and # CpGs). Each row corresponds to a given training dataset, each column
to a test dataset. Models are ordered according to Eval1-EV1dist, rank 1 corresponds to the model with the largest value. Eval1 is the normalized
largest eigenvalue of the covariance matrix taken from the methylation matrix of the test data. EV1dist is the Euclidean distance between the
leading Eigenvectors of the model’s covariance matrix in the training data and in the test data. The black line shows the mean number of CpGs
used in the models up to the indicated rank, normalized by the maximum number of CpGs considered (1500). The other lines correspond to the
mean weights (see Methods) used in the models up to the indicated rank. Blue lines correspond to average methylation difference (t- or MWU
test), red to methylation variation difference (Bartlett’s or Levene’s test) and green to methylation-age-correlation. Solid lines indicate models
taking into account both hyper- and hypomethylated CpGs. Dashed lines represent models using only hypermethylated and dotted lines indicate
models using only hypomethylated CpGs.
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respond to the numbers given [10] and compared to the
AUCs of the top 20 ranking MS-SPCA models, p <
0.001. It can be seen that the numbers reported by the
EVORA authors [10] are better than those from our
own runs. The original EVORA method [10] and the
‘evora’ R-package do not consider any information about
the age of the women who have provided the samples,
although this was considered in a related paper [15]. It is
possible that the higher numbers result from taking age
into account. However, MS-SPCA outperforms these re-
sults as well. Moreover, MS-SPCA was also performing
well without the use of age information. The results are
similar to the ones presented in Table 6, mostly lower by
about 0.01-0.02, but higher in the case of Normal HPV-
→CIN2+(b) by 0.04.
Description of best performing models
A concise description of the models used for predictions
is shown in Figure 3. Models were sorted according to
Eval1-EV1dist and mean values were calculated frommodel rank 1 up to any other indicated rank. For in-
stance, rank 5 shows the mean numbers of the first 5
models. Accordingly, the final rank shows the mean
values of all the models used. Interestingly, the figures in
a given row are similar, indicating that the model order
is also similar for different test data predictions. Best-
ranking models typically contain fewer CpGs (black
line). Clearly, solid lines are dominating amongst the
coloured ones. That means most of these models include
hyper- and hypomethylated CpGs, models with pure
hyper- or hypo-CpGs are rare. The models selected from
cross-validation within Normal and Normal HPV+ data
contain CpGs which are mostly ordered by methylation
variation difference, the red line ends at >60% (~2/3 cor-
respond to Bartlett’s test ordering, 1/3 to Levene’s test).
Models in rows 3–5 are dominated by methylation dif-
ference ordering (>1/2 t-test in rows 3 and 5, ~2/3
MWU in row 4).
The best performing models (low ranks) are domi-
nated by age-correlation in the Normal training data
(rows 1–3) and by methylation difference in row 4.
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(the features specifically selected by EVORA [10]) are
dominating in the best predicting models in row 5.
Cytologically normal samples contain DNAm patterns
predisposing for later transformations
Samples classified as normal by the standard cytological
screening method contain DNAm patterns that can clearly
differentiate between normal and CIN2+ samples and be-
tween normal and cancer samples (Figure 2 and Table 6).
Interestingly, this conclusion even holds for the Normal
HPV- samples. Although HPV infection is considered a ne-
cessary condition for neoplastic transformation and later
cancer, the differentiating DNAm patterns exist prior to
any HPV infection. These patterns might contribute to in-
fection itself and/or contribute to transformations after in-
fection. The latter possibility is supported by our finding
that MS-SPCA trained on Normal HPV- data predicts the
phenotype of Normal HPV+ samples about as well as when
trained on CIN2+ data.
To further study the problem of phenotype prediction
within the Normal data, a corresponding stratified 5-fold
cross-validation was performed. Both the Normal HPV+
and the Normal HPV- datasets were subdivided into five
equally sized case–control parts, always ensuring that
age is matched. Five predictions were performed, taking
one set for testing and the remaining four as training
data. Additional file 1: Figures S2-S4 show the plots cor-
responding to Figures 1, 2 and 3 for the five cases using
Normal HPV+ data for training, and Additional file 1:
Figures S5-S7 the same using Normal HPV- for training.
Clearly, Eval1-EV1dist is an important sorting criterion,
for instance in cancer prediction from Normal HPV-
data. However, Additional file 1: Figures S3 and S6 also
show that this sorting is selecting the best predicting
models in the test data corresponding to the trainingTable 7 Prediction performance (AUC) of MS-SPCA, using Nor












Rows correspond to training datasets and columns to test datasets. The first numbe
(mean value of 8 runs). Bold numbers show best predictions.data (first column) less robustly. Our hypothesis that this
is caused by the small size of these test sets (<10 cases
and controls) was confirmed by a corresponding calcula-
tion (Additional file 1: Figure S8). The larger the test sets
are the better Eval1-EV1dist selects the best predicting
models. This implies that MS-SPCA would predict fu-
ture transformations better in larger test data. Table 7
shows the results of the final MS-SPCA prediction using
the cumulative score of the first 5 models, in compari-
son to EVORA predictions. MS-SPCA prediction results
are better and more consistent (less variable) than
EVORA results. Again, in most cases the advantage of
MS-SPCA is statistically significant. MS-SPCA allows
the prediction of later neoplastic transformation in HPV
infected women with cytologically normal samples
(mean AUC = 0.60).
Finally, we also tested if DNAm patterns might con-
tribute to infection itself by using the models trained on
Normal HPV- data to predict independent test data
where the “cases” are healthy HPV+ samples (women re-
main cytology negative for 3 years) and controls are
healthy HPV- samples. Interestingly, this ‘phenotype’ can
be predicted even better than the future transformation
in the Normal HPV+ data: AUC > 0.8 (Additional file 1:
Figure S9). This indicates that DNAm patterns may con-
tribute to HPV infection.
Consistency of models used for predictions, corresponding
outstanding CpGs and genes
All phenotype predictions were based on the five models
with the largest parameter Eval1-EV1dist (see Methods).
Interestingly, the five models chosen for the prediction
of different test data were often identical. For example,
three of the five models from the training data Normal
that were used to predict CIN2+(a), CIN2+(b) and Can-
cer (first row in Figures 1, 2 and 3) are identical, i.e.mal data for training
Normal HPV- CIN2+(a) CIN2+(b) Cancer
0.50/0.38 0.91/0.78 0.86/0.65 1/0.73
0.52/0.41 0.93/0.69 0.76/0.53 1/0.52
0.54/0.49 0.93/0.84 0.85/0.70 1/0.70
0.50/0.56 0.93/0.74 0.84/0.64 1/0.79






r shows the performance of MS-SPCA, the second the performance of EVORA
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very well. Similar model consistency was also found using
other data for training: Normal HPV+ and HPV- were
used to predict four independent test data, CIN2+(a) and
CIN2+(b) to predict five test data (cf. Table 6). The cor-
responding intersection of the 4x5 or 5x5 models is 1,
3, 3 and 0, respectively. Although there is no model
amongst the five best that is used for all five test data
predictions in the case of training data CIN2+(b), one
model is consistently used to predict the four test data
Normal, Normal HPV+, CIN2+(a) and Cancer; three of
the models used to predict Normal HPV- were also
used to predict Cancer.
Not surprisingly, the CpGs used in the five models for
final prediction are also largely overlapping. Further-
more, the CpGs of all the five models used to predict
one test dataset tend to overlap with the corresponding
CpGs used to predict another test dataset. The numbers
of common CpGs used for the prediction of all test data-
sets based on the five training datasets Normal, Normal
HPV+, Normal HPV-, CIN2+(a) and CIN2+(b)) are 235,
75, 171, 238 and 89, respectively. For instance, 235 same
CpGs were used to predict CIN2+(a), CIN2+(b) and
Cancer from the training dataset Normal. There is one
CpG occurring in all these five CpG lists: cg11965370,
located in a CpG island 234 bp upstream of the tran-
scription start site (TSS) of the NTM gene. NTM codes
for the protein neurotrimin, which is known to play a role
in cell-adhesion [22]. The intersection of the 235, 238 and
89 CpGs is cg00027083, cg11965370, cg16638540, cg22415
432, cg22881914, cg25044651, cg26186727 and cg26363
196, which are all hypermethylated in all six datasets.
Although there is no CpG with significant methylation
difference between cases and controls in the three Normal
data (Table 2), there are CpGs consistently used for the pre-
diction of test data. The intersection of the 235, 75 and 171
CpGs is cg02008154, cg02250594, cg02624705, cg06277657,
cg11965370, cg12457773, cg13870866, cg17727529, cg1786
1230, cg23303408, cg23316360, cg23710218, cg26963271,
nearly all are hypermethylated in all six datasets.
139 CpGs occur in at least two of the five CpG lists
with 130 of them being located in CpG islands, mostly
close to the TSS (Additional file 2: 139CpGs.xlsx).
Nearly all are hypermethylated in the analysed six data-
sets, but two are clearly hypomethylated: cg07251788 in
all six datasets, cg08214029 in five datasets. They corres-
pond to the genes CCL18 and CLTCL1, respectively.
Both are often overexpressed in cancer cells. Elevated
CCL18 expression plays a role in ovarian carcinoma [23]
and induces metastasis of breast cancer [24]. CLTCL1 is
overexpressed in cervical and other cancers [25-27].
Two genes correspond to more than two of the 139
CpGs, both are well-known tumour suppressor genes:
DCC (DCC =Deleted in Colorectal Cancer) and GATA4.The GATA4 promoter is hypermethylated in cancer [28]
and it is involved in ovarian cancer [29-31]. Interestingly,
the two most important human DNA regions of a recent
DNAm cervical pre-cancer classifier, EPB41L3 and
DPYS [32], are amongst the ~100 regions corresponding
to the 139 CpGs.
Discussion
We have developed MS-SPCA, an advanced version of
the classifier SPCA [12]. In contrast to SPCA, MS-SPCA
considers several models that perform well in training
data cross-validation and selects the final ones for pre-
diction of test data, based on parameters obtained from
the test data. We tested different parameters and param-
eter combinations based on the training data but none
was performing as well in selecting the best models as
our final criterion Eval1-EV1dist.
Importantly, the values of the parameters Eval1 and
EV1dist are related to the prediction performance. For in-
stance, Figure 1 shows that, using CIN2+(b) for training, all
corresponding models have relatively poor parameters
Eval1 and EV1dist, compared to the cases using datasets
Normal or CIN2+(a) for training. Accordingly, the predic-
tion performance using the CIN2+(b) dataset for training is
lower (Figure 2). Consideration of >1 PC might improve
the prediction. It seems that parameters such as Eval1 and
EV1dist could provide the basis for automatic selection of
the most appropriate number of principal components to
consider. We also tested a support vector machine (SVM)
for prediction using more than one PC, but without any
specific criterion for model selection. The corresponding
performance was slightly lower, but a combination of an
automatic selection of the number of PCs to consider with
advanced learning algorithms such as SVM could lead to
further improvement.
Another point for potential future improvement con-
cerns the number of models to consider. Here we used
the few hundred best models according to training data
cross-validation performance. Obviously, some diversity
of the models is needed such that the final model selec-
tion criterion Eval1-EV1dist can select the most appro-
priate ones. Considering only the very few in the
training data top performing models might suffer from
too low model diversity and over-fitting to the training
data, considering many models is time consuming and
might result in over-fitting to the test data. Maybe some
optimal diversity (in terms of different weights and num-
ber of CpGs and/or different CpGs contained in the
models) can be defined, helping to automatically select
the cross-validation performance cut-off and therefore
the number of models to consider.
We have shown that the model selection of MS-SPCA
works better the more samples the test set contains. In
the special case that the test set contains only one
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The corresponding phenotype could be predicted by ei-
ther a majority vote of all the models (selected from
training data cross-validation) and/or by assigning add-
itional samples to the test set (for instance taking some
from the initial training set, but not using them for
training) and applying the criterion Eval1-EV1dist.
MS-SPCA was applied for phenotype prediction from
genome-wide DNA methylation data. The procedure in-
volves the following steps: 1) splitting of the training
data into k-fold training and test sets (here we used the
LOO method), 2) calculation of p-values for all CpGs (in
each of the k training datasets) for the three features of
a CpG’s methylation: average methylation difference,
methylation variation difference and methylation-age-
correlation, 3) identification of the best models in train-
ing data cross-validation: testing models with different
weights (combining the three p-value rank lists) and
numbers of CpGs in each of the k training datasets 4)
predicting the independent test data with the best per-
forming models identified in step 3 (here we used the
few hundred best models), 5) the Model Selection step
of MS-SPCA: ranking these models according to the cri-
terion Eval1-EV1dist and using the cumulative risk
scores of the first n best ranking models for final predic-
tion (here we used n = 5). We have shown that MS-
SPCA performs better than the recent method EVORA
[10].
The first experiments on DNA methylation in human
cancer showed widespread hypomethylation [13], but after
the discovery of tumour suppressor genes one also ob-
served promoter hypermethylation [33,34]. Meanwhile, of
all epigenetic modifications, hypermethylation of promoter
regions of tumor suppressor genes has been most exten-
sively studied [35]. We have shown that hypermethylation
and hypervariability are important factors for neoplastic
transformation, but hypomethylation and hypovariability
play a role as well. The 27K CpGs analysed here are biased
towards hypermethylated promoter regions [10]. Neverthe-
less, MS-SPCA performs best if both hyper- and hypo-
methylated CpGs are considered. It will be interesting to
see if hypomethylated CpGs play an even bigger role in
more recent larger and less biased DNA methylation
assays.
It has been suggested that hypervariable CpGs are most
important for the prediction of early cancer development
[15], although analysis of other cancer data does not always
benefit from considering differential variability [10]. This is
in agreement with our results (Figure 3). MS-SPCA in
combination with the here presented CpG selection
method allows for automatic identification of the most ap-
propriate weighting of the CpG’s methylation features.
Although HPV infection is considered necessary for
cervical cancer development [36], we have shown thatspecific DNA methylation patterns which are likely con-
tributing to later cancer development exist already be-
fore any HPV infection. This is in accordance with
previous findings that epigenetic changes may be the
earliest initiating factor in a human cancer [7]. On the
other hand, it was recently suggested that the earliest
changes leading to later transformations might be other
epigenetic changes such as chromatin modification ra-
ther than DNA methylation [33]. If this is true, then the
patterns observed in the Normal data may be the conse-
quence of other earlier epigenetic changes. However,
even then the analysis of DNA methylation can be im-
portant for early diagnosis of dangerous transformations
as it is detectable before standard cytological screening
methods can show evidence of transformations [16].
We have presented evidence that DNA methylation
patterns exist in cytology normal HPV- samples that (i)
predispose to neoplastic transformations after HPV in-
fection and (ii) predispose to HPV infection itself. It will
be interesting to test if other virus infections are also
correlated with specific DNA methylation patterns.
Given that MS-SPCA performs well using data from
comparatively few samples and only 0.1% of the GpGs in
the human genome [2], it is possible that future DNA
methylation analysis can provide the accuracy needed
for clinical applications.
Conclusions
MS-SPCA, an advanced version of the classifier SPCA,
is presented. It performs well in predicting phenotypes
from genome-wide DNA methylation data. MS-SPCA
can be applied to other classification problems. Consid-
eration of more principal components, based on the
automatic selection of the corresponding most appropri-
ate number, and additional model selection methods
might allow further improvement.
Methods
Data
Four independent age-matched case–control datasets
were analysed, all freely available from the Gene Expres-
sion Omnibus repository [37], accession numbers
GSE20080, GSE30760 (SuperSeries comprising GSE3
0758 and GSE30759) and GSE37020. CpG methylation
was measured using Illumina’s Infinium Human Methy-
lation 27K Beadchips [38] and corresponding β-values
were calculated for 27,578 CpGs: β =M/(U +M + e),
where U and M are the unmethylated and methylated
intensity values of the CpG and e is a small correction
term [10]. The four datasets are labeled according to
the cancer stage of case samples (Normal, CIN2+(a),
CIN2+(b) and Cancer): (1) Normal: 152 samples in a
prospective case–control study (matched for human
papillomavirus (HPV) status and age) - 75 women with
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CIN2+ after 3 years in round 2 (=cases) and 77 control
women with normal cytology in rounds 1 and 2, (2)
CIN2+(a): 48 samples (age-matched) with 18 cases
(CIN2+, all HPV+) and 30 controls (normal cytology,
HPV+ and HPV-), (3) CIN2+(b): 48 samples (all HPV+
and age-matched) with 24 cases (CIN2+) and 24 con-
trols, (4) Cancer: 63 samples (age-matched) with 48
cases (cervical cancer) and 15 controls (no HPV infor-
mation). Additionally, the 152 Normal samples were
split into two datasets: 92 HPV+ (44 cases, 48 controls)
and 60 HPV- (31 cases, 29 controls), yielding together
six datasets (Table 1).Quality control and normalization
The six datasets were processed by the following proced-
ure: Missing values were replaced by the CpG’s mean
and CpGs were mean-centered. Batch effects were de-
tected, for instance strong correlation of leading princi-
pal components to the bisulfite conversion efficiency
(BSCE) in Normal data. To remove such known and
additional unknown batch effects we adjusted the data
using Surrogate Variable Analysis [39] (bioconductor R-
package ‘SVA’), keeping age and phenotype as variables
of interest. Using the default method “be”, 5, 5, 4, 2, 4
and 13 surrogate variables were found in Normal, Nor-
mal HPV+, Normal HPV-, CIN2+(a), CIN2+(b) and
Cancer, respectively. The data were adjusted accordingly.
After adjustment no significant correlation of BSCE to
leading principal components could be detected. Finally,
data were COPA transformed (Cancer Outlier Profile
Analysis [40]).Feature selection: testing for average methylation
differences, methylation variation differences and
methylation-age-correlation, corresponding combinations
Traditionally, DNAm analysis tested for differences be-
tween the average methylation of case and control
samples [33], but different methylation variability [9]
and methylation-age-correlation [41] can be additional
indicators of risk CpGs [15]. We therefore tested for dif-
ferential methylation, differential variability and age-
correlation of CpGs in the six datasets. It is not a priori
clear which test is most appropriate for differential
methylation and differential variability in our context
(i.e. which test gives the best prediction results), so we
used two different tests in each case: differential methy-
lation was quantified by t-test and Mann–Whitney U
test, differential variability by Bartlett’s test and the
much less outlier sensitive Levene's test (Brown–For-
sythe test gave results between Bartlett’s and Levene’s,
but generally close to Levene’s, so was not considered
any further). Methylation-age-correlation was tested bycomparing the test statistic r=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−r2ð Þ= n−2ð Þp to a
t-distribution (n = #samples, r = Pearson’s correlation
coefficient, df = n-2). Together, the tests give five (two-
sided) p-values per CpG (per dataset). The most signifi-
cant CpGs, according to a t-test for instance, contain
both hyper- and hypomethylated sites. The method
EVORA [10] uses only hypermethylated and hypervari-
able CpGs. To also study the prediction performance of
MS-SPCA based on pure hyper- or hypo-sites we assign
10 additional p-values (5 ‘hyper-p-values’ and 5 ‘hypo-p-
values’) to each CpG, yielding altogether 15 p-values per
CpG (per dataset). This is done by the following
scheme: the hyper-t-test-p-value equals the calculated t-
test-p-value if the mean methylation of the case samples
is larger than the mean methylation of the control sam-
ples, otherwise we set hyper-t-test-p-value = 1. Equiva-
lently, the hypo-t-test-p-value can only be <1 if the
mean methylation of the case samples is smaller than
the mean methylation of the controls. The ‘hyper-‘and
‘hypo-p-values’ for the other tests were obtained by a
similar procedure.
Genome-wide significance was found by calculation of
corresponding q-values (measure of false discovery rate
[42]), using the R library ‘qvalue’. ‘Hyper-‘and ‘hypo-q-
values’ were obtained by only considering the subsets of
CpGs with corresponding p-values < 1.
The 15 p-values per CpG allow 15 different (‘simple’)
CpG orders for later usage in the supervised PCA (see
below).Additional CpG orders by combining ‘simple’ ones – ‘combi’
orders
By combining different ‘simple’ CpG orders we obtain add-
itional ‘combi’ orders. Combining p-values to get new or-
dered lists is an interesting problem in its own right, a new
combination of two p-values was recently suggested [43].
Here we use a simple ranking method to combine any
number of lists: first, the ranks of all CpGs in all lists are
calculated. Adding of rank-lists produces an equal-weight
new rank-list. Ordering according to ascending rank-sums
gives a final ‘combi’ order. CpGs with low rank sums
are the most significant ones. Instead of just simple sum-
mation (equal weights), multiplication with a corresponding
weight-vector allows arbitrary weighting of lists. Appropri-
ate weights could for instance correspond to significance
ratios (or the corresponding log) of most significant ele-
ments. We consider combinations of three test results
(a differential methylation test, a differential variability test
and the age-correlation test). The relative importance of
each test result is expressed by a three-dimensional weight
vector. We use the following method to evenly sample the
combinations space: (1,0,0) indicates CpG ranking accord-
ing to a test for average methylation difference (t- or MWU
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variation difference (Bartlett’s or Levene’s test) and (0,0,1)
ranking according to methylation-age-correlation. We sys-
tematically tested many different weight vectors, ranging
from (1,0,0) to (1,29,29) in steps of factor 2, i.e. 277 different
vectors (all pairwise cosine distances > 0). Note that a rank-
ing according to for instance the weight vector (1,29,29)
yields nearly the same best ranking CpGs as a ranking ac-
cording to (0,1,1), so this systematic sampling covers the
combinations space.
Creation of models to be tested in training data
cross-validation
For each given weight 30 different numbers of best rank-
ing CpGs were tested (50,100,150,…,1500). Together, we
tested 4×277×30 = 33,240 models (4 combinations of the
two different tests for average methylation difference
and methylation variation difference). The tested CpG-
lists contain both hyper- and hypo-sites; for instance
CpGs ordered according to a t-test contain hyper- and
hypo-methylated sites, CpGs ordered according to
Levene’s test contain hyper- and hypo-variable sites. We
found that the type of test (t or MWU, Bartlett’s or
Levene’s) is less important than the parameters weight
and number of CpGs tested. We tested additional
models taking into account only t-test and Bartlett’s test
rankings (21 different weights, from 1,0,0 to 1,29,0), for
the three cases of CpG lists containing hyper- and hypo-
sites, only hyper-sites (i.e. only hypermethylated and hy-
pervariable) and only hypo-sites, together 3×21×30 =
1,890 models. In total 35,130 models were tested for
cross-validation performance (in a given training
dataset).
Selection of models performing well in training data
cross-validation
In cross-validation, parts of the data are used for training
and the complement for testing. Here we used the leave-
one-out method (LOO), but 5- or 10-fold cross-validation
could be used instead. The most significant CpGs were
identifed in the training data (the training part of the train-
ing data) and the corresponding first principal component
was calculated (training-PC1). Using the same CpGs in the
test data (the test part of the training data), test-PC1 was
obtained by multiplication of the test data methylation
matrix with the leading Eigenvector of the training data co-
variance matrix. Based on the coordinates of samples on
the training-PC1, together with the known phenotype
(known in training data), prediction of test data was done
according to the coordinates of samples on the test-PC1.
Using this method prediction accuracies were obtained for
all the 35,130 models tested.
The original SPCA method [12] would use the model
performing best in the training data for prediction ofindependent test data. However, we found that the model
with the best cross-validation performance is often not the
best model for prediction of independent test data. Using
the CIN2+(b) data for training we also found many models
with cross-validation prediction accuracy = 1, so this par-
ameter is not sufficient to select one best model.
Model-selection-supervised principal component analysis
(MS-SPCA)
Instead of picking just one model for independent test data
prediction Model-Selection-SPCA (MS-SPCA) considers
many models performing well in the training data cross-
validation and from these selects specific models for final
prediction, according to additional parameters obtained
from the test data. We use the two parameters Eval1 and
EV1dist which carry partly independent information. Eval1
is the normalized largest eigenvalue of the covariance
matrix Covtest (taken from the methylation matrix of the
test data), considering only the CpGs from the given model.
EV1dist is the Euclidean distance between the leading Ei-
genvectors of Covtrain and Covtest (the model’s covariance
matrix in the training data and in the test data). The smaller
EV1dist and the larger Eval1, the more likely the model
fits well to the test data and makes a good prediction (cf.
Figure 1). All models were ordered according to the single
parameter Eval1-EV1dist (standardized numbers). Figure 2
shows that this ordering correlates well with the prediction
performance measure AUC. Finally, to increase the robust-
ness of prediction, we calculated cumulative risk scores
for the test samples by adding the risk scores of the first
1,2,3,… models (ordered by Eval1-EV1dist). Red curves in
Figure 2 show the corresponding AUC. The final prediction
results (Tables 6 and 7) correspond to the cumulative risk
scores from the first n = 5 models (n = 1 means taking the
single best ranking model alone for prediction, any n < 100
gives very similar results).
Mathematica code performing all steps from feature se-
lection to MS-SPCA is provided in the Additional file 3.
Enrichment analyses
Known cervical cancer genes were taken from the Cervical
Cancer Gene Database (CCDB [19]), and developmental
genes (PCGTs) from [18]. Enrichment was calculated with
a hypergeometric test, using 27,578 and 20,000 as back-
ground sample sizes for genome scale CpG- and gene-
enrichment analyses, respectively.
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Additional file 1: Contains supporting information. Figure S1.
Performance of the first four principal components in separating cases
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